Ali Nadhim
Pulmonary Disease · Little Silver, NJNPI 1376059717
Payments from drug & device makers
Across 146 payments — averaging $25.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$689
- GSK$689
- Philips North America LLC$377
- Avadel CNS Pharmaceuticals, LLC$348
- Regeneron Healthcare Solutions, Inc.$276
- Inspire Medical Systems, Inc.$262
- plus $1K from 13 others
What the payments were for
- Food & beverage$3,43291%
- Education$3259%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 22 | $689 |
| GSK | 42 | $689 |
| Philips North America LLC | 20 | $377 |
| Avadel CNS Pharmaceuticals, LLC | 11 | $348 |
| Regeneron Healthcare Solutions, Inc. | 5 | $276 |
| Inspire Medical Systems, Inc. | 7 | $262 |
| Jazz Pharmaceuticals Inc. | 4 | $253 |
| Sanofi | 5 | $210 |
| United Therapeutics Corporation | 8 | $178 |
| Sanofi-aventis U.S. LLC | 1 | $79 |
| Pfizer | 5 | $79 |
| ANI Pharmaceuticals, Inc. | 5 | $74 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $55 |
| Actelion Pharmaceuticals US, Inc. | 1 | $55 |
| Harmony Biosciences LLC | 2 | $34 |
| Amgen | 2 | $31 |
| Boston Scientific | 1 | $29 |
| Lilly USA, LLC | 1 | $24 |
| Boehringer Ingelheim | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,757 in reported general payments places this provider in the 60th percentile of 472 pulmonary disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 137 | $97,644 |
| Breo ElliptaFluticasone/Vilanterol | 53 | $20,398 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 31 | $19,015 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $10,263 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 20 | $9,370 |
| EliquisApixaban | 16 | $8,788 |
| Spiriva RespimatTiotropium Bromide | 15 | $7,637 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $3,463 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 100 | $3,062 |
| Wixela InhubFluticasone Propion/Salmeterol | 11 | $1,782 |
| Ventolin HfaAlbuterol Sulfate | 14 | $1,059 |
| Fluticasone Propionate | 14 | $186 |
| Prednisone | 29 | $122 |
| Azithromycin | 17 | $102 |
| Ropinirole Hcl | 14 | $30 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $689 | $128,305206 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $689 | $22,47946 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $14 | $17,00735 claims |
| PfizerEliquis | $79 | $8,78816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 472 pulmonary disease providers in New Jersey.
Other pulmonary disease in Little Silver
- Reynold PanettieriNew Brunswick$2.5M
- Vinay SikandToms River$1.8M
- Stanley FielMorristown$1.3M
- Joseph HoffmanPark Ridge$1.1M
- Robert SussmanSummit$645K
- Ronaldo GoHackensack$563K
- Deborah GossHackensack$558K
- Sabina HussainNew Brunswick$555K
- Manuel CunananMillville$489K
- Emanuele SantomauroHackensack$420K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.